KITCL27
Idiopathic Pulmonary Fibrosis
PreclinicalActive
Key Facts
About Kither Biotech
Kither Biotech is a private, clinical-stage company developing inhaled therapies for rare respiratory diseases with high unmet need, notably cystic fibrosis and idiopathic pulmonary fibrosis. Its lead asset, KIT2014, an orphan drug-designated dual PDE3/4 inhibitor peptide, successfully completed Phase 1 in 2025, with Phase 2 planned for 2026. The company has raised significant venture capital, including a €5.6M Series A and an €18.5M Series B in 2022, to advance its pipeline and is built on strong academic roots from the University of Turin.
View full company profileTherapeutic Areas
Other Idiopathic Pulmonary Fibrosis Drugs
| Drug | Company | Phase |
|---|---|---|
| BIO 300 | Humanetics Corp. | Research |
| BRS101 | BreStem Therapeutics | Phase 1 |
| T03 | Treamid Therapeutics | Phase 1 |
| Pirfenidone | Gyre Therapeutics | Marketed |
| PIPE-791 | Contineum Therapeutics | Phase 1 |